×

Notice

The forum is in read only mode.
Welcome, Guest
Username: Password: Remember me
  • Page:
  • 1

TOPIC:

Malaysia says "No" to Gilead Monopoly 6 years 7 months ago #25259

  • DrJames
  • DrJames's Avatar Topic Author
  • Offline
  • Platinum Member
  • Platinum Member
  • Posts: 1980
  • Karma: 111
  • Thank you received: 7263
Today, which happens to be my birthday, Malaysia gave its citizens a present. Cabinet has agreed to issue a compulsory licence on the Gilead HCV medication Sofosbuvir.

www.themalaymailonline.com/malaysia/arti...hepatitis-c-generics

What this means is the Sofosbuvir patent can be ignored and Malaysia will be able to import generic Sofosbuvir.

So what about Ledipasvir and Daclatasvir, afterall we need 2 drugs.

No this won't impact that but it turns out DNDi, Pharco and Presidio have a rather tidy pan-genotypic NS5A inhibitor called Ravidasvir, which was co-incidentally trialled in Malaysia. This is essentially the same as Velpatasvir.

So no prizes for joining the dots. Sofosbuvir+Ravidasvir - coming to a town near you (at least if you live in Malaysia).

More on Ravidasvir here: www.dndi.org/diseases-projects/portfolio/sofosbuvir-hepc/
YMMV
The following user(s) said Thank You: Gaj, splitdog, Greedfighter, Sven, Mnem

Malaysia says "No" to Gilead Monopoly 6 years 7 months ago #25260

Happy Birthday, Doc!! :)
This email address is being protected from spambots. You need JavaScript enabled to view it.

Genotype 3
VL 4,100,000
ALT 101 AST 71
Treatment Naive
Started Sof/Dac Jan 12, 2016
VL= <15 4 weeks in. AST/ALT normal.
VL=UNDETECTED 8 weeks in.
SVR4= Virus back. 3,300,000

Started generic Epclusa Sep. 23, 2017

4 weeks in <15 *Detected.
12 weeks in <15 *Not Detected.
16 weeks in <15 *Not Detected.
Finished 24 weeks treatment 3-17-18
SVR5 <15 Not Detected.
SVR 20 <15 Not Detected.
SVR 44 <15 Not Detected.

Thank you Jesus.
Thank you Dr. James
The following user(s) said Thank You: DrJames, Greedfighter
  • Page:
  • 1
Time to create page: 0.062 seconds

Copyright © 2015-2020 FixHepC

Back to Top